_MG_4679-2.jpg
_MG_4679-2.jpg

microRNAs and Cancer


MicroRNAs, or miRNAs, are a novel class of molecules that control most functions in the body. A single miRNA can regulate over 100 cancer-promoting molecules, so their expression and regulation is extremely important for maintaining healthy cells. 

SCROLL DOWN

microRNAs and Cancer


MicroRNAs, or miRNAs, are a novel class of molecules that control most functions in the body. A single miRNA can regulate over 100 cancer-promoting molecules, so their expression and regulation is extremely important for maintaining healthy cells. 

 

MicroRNA (miRNA) therapeutics represent the new frontier in the fight against human disease. The importance of miRNAs in cancer development, and their potential to reverse it, are only beginning to be unraveled. 

Deficiencies in microRNA levels lead to overexpression of proteins that promote cancer aggressiveness, including traits such as tumor cell growth, spread, and resistance to chemotherapy. 

Using the latest in nanotechnology and synthetic biology we can reintroduce these missing microRNAs into tumor cells, stopping and reversing the spread of cancer. 

Our technology has been demonstrated, in peer-reviewed publications, to work both alone and in combination with existing cancer-fighting agents to reduce tumor burden and metastasis, improving the effectivity of currently used treatments.

 

Management


Management

Management


Management

Christian Marin-Müller, CEO: 

(PhD, Molecular Virology and Microbiology, Baylor College of Medicine; MS, Entrepreneurial Biotechnology, Case Western Reserve University/Weatherhead School of Management; BS, Molecular Biology, Florida Tech)

Dr. Marin-Müller has worked in the field of cancer therapeutics for almost a decade, with a specific focus on the use of RNA interference technology and development of nanotechnology-based delivery of therapeutics against solid tumors. 

He is co-inventor of a therapeutic miRNA treatment that can control a network of biomarkers responsible for aggressive growth and metastasis in pancreatic cancer, and has the potential to completely eliminate tumors both alone and in combination with existing modalities.

In addition to his focus on research, Dr. Marin-Müller has also been heavily involved in the biotech industry ecosystem. He has co-founded several biotechnology and service companies, and has worked as a consultant to multiple start-up and governmental organizations, contributing to the development of projects ranging from medical devices to HIV vaccine investigation.

Board of Advisors


Board of Advisors

Board of Advisors


Board of Advisors

  • QIZHI CATHY YAO, M.D., PH.D.

    • Professor of Surgery, Division of Surgical Research, Baylor College of Medicine, Houston, TX, US

    • Professor Molecular Virology & Microbiology, Pathology & Immunology, Baylor College of Medicine, Houston, TX, US

  • CHANGYI JOHNNY CHEN, M.D., PH.D.

    • Professor of Surgery and Chief, Division of Surgical Research, Baylor College of Medicine, Houston, TX, US

    • Molecular Surgery Endowed Chair, Baylor College of Medicine, Houston, TX, US

    • Director, Molecular Surgeon Research Center, Molecular Surgeon Research Center, Baylor College of Medicine, Houston, TX, US

    • Professor Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, US

  • PETER HEECKT, M.D., PH.D

    • Co-founder and Managing Member, Life Sciences Consulting Services LLC

    • Chief Medical Officer, Bioventus

    • Chief Medical Officer, Smith & Nephew

  • THILO BAYRHOFFER, M.D., PH.D

    • Physician, EM Lifescience Partners LLC

    • Managing Director and Partner, Speratum Ltd.

    • Managing Director and Managing Partner, Novumed LLC

    • Managing Director and Partner, Effimed Consulting & Advisory

    • Executive Director, Ramparts Asset Management Company LLC

    • Managing Director and Partner, Effimed Research LLC

    • Managing Director and Partner, Empartners consulting

  • MIN LI, PH.D

    • Professor of Medicine, Surgery, and Cell Biology

    • Virginia Kerley Cade Endowed Chair in Cancer Treatment

    • Director of GI Cancer Research, Department of Medicine

    • Vice Chair for Research, Department of Surgery

  • GUILLERMO RODRIGUEZ, M.D.

    • Founder, Costarican Institute for Clinical Research

    • Professor of Medicine, University of Costa Rica

    • Adjunct Professor, Baylor College of Medicine, Houston, TX, US

    • Senior Medical Advisor, Harvard Medical International